Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Shinjuku, TokyoFounded 19192,494 employeesWebsite
A global leader in medical equipment with a 70% share of the gastrointestinal endoscope market. Leverages precision optical technology to advance minimally invasive surgery and early diagnosis.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Gastrointestinal Endoscopy Solutions | 69% | ¥697.4B | ¥136.4B | 19.6% |
| Surgical Intervention Business | 31% | ¥313.1B | ¥-15.0B | -4.8% |
Close (Oct 30, 2026)
¥1,742-9.4% (1Y)
Olympus -9.4% over 1Y, 18.2pt below the industry average (9 companies, +8.8%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥1.0T | ¥97.1B | ¥68.2B | ¥1.5T | +1.3% |
| 2025FY | ¥997.3B | ¥162.5B | ¥117.9B | ¥1.4T | +7.7% |
| 2024FY | ¥925.8B | ¥51.4B | ¥242.6B | ¥1.5T | +5.0% |
| 2023FY | ¥881.9B | ¥186.6B | ¥143.4B | ¥1.5T | +17.6% |
| 2022FY | ¥750.1B | ¥146.2B | ¥115.7B | ¥1.4T | +2.7% |
| 2021FY | ¥730.5B | ¥82.0B | ¥12.9B | ¥1.2T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Mar 2025)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
